To analyze miR‐484 expression in DN and its association with clinicopathological parameters, as well as to elucidate its molecular regulation of Sodium–glucose cotransporter protein 2 (SGLT2), providing evidence for the early diagnosis of DN and miR‐484/SGLT2‐targeted therapies. The gene discussed is SLC5A2; the disease is liver dysplastic nodule.